ena-STUDY-SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE-23-10-2020-01:27:03:466-172
Predictive biomarkers for responsiveness to FOLFOX in gastric cancers based on integrative profiling of patient-derived xenografts
Gastric cancer (GC) is the second leading cause of cancer-associated death worldwide. Curative surgery followed by systemic chemotherapy containing 5-fluorouracil (5-FU) derivatives and platinum combination chemotherapy is the standard of care for GC patients. However, there is a lack of the clinically applicable predictors of FOLFOX (folinic acid, 5-FU and oxaliplatin) combination chemotherapy. Herein, we developed patient-derived xenograft (PDX) models from 31 GC patients treated with combination of 5-FU and oxaliplatin to provide predictive biomarkers for drug responsiveness based on extensive genomic and transcriptomic characterization of chemotherapy responsiveness of tumors.
Gastric cancer (GC) is the second leading cause of cancer-associated death worldwide. Curative surgery followed by systemic chemotherapy containing 5-fluorouracil (5-FU) derivatives and platinum combination chemotherapy is the standard of care for GC patients. However, there is a lack of the clinically applicable predictors of FOLFOX (folinic acid, 5-FU and oxaliplatin) combination chemotherapy. Herein, we developed patient-derived xenograft (PDX) models from 31 GC patients treated with combination of 5-FU and oxaliplatin to provide predictive biomarkers for drug responsiveness based on extensive genomic and transcriptomic characterization of chemotherapy responsiveness of tumors.